SC 26196是一种具有口服活性的Delta6去饱和酶（D6D, FADS2）抑制剂，SC 26196可抑制亚油酸和α-亚麻酸向长链不饱和脂肪酸的转化以调控脂质代谢。
Cas No.:218136-59-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SC 26196 is an orally active Delta6 desaturase (D6D, FADS2) inhibitor that regulates lipid metabolism by inhibiting the conversion of linoleic acid and α-linolenic acid into long-chain unsaturated fatty acids[1-2]. SC 26196 is applicable for research related to inflammatory diseases and lipid metabolism disorders[3-4].
In vitro, in skin fibroblasts, coronary artery smooth muscle cells, and astrocytes, SC 26196 (2μM; 24 hours) inhibited the desaturation of 2μM [1-14C]18:2n-6 and significantly reduced the synthesis of arachidonic acid, EPA, and DHA[5]. During the differentiation of 3T3-L1 adipocytes, SC 26196 (5μM; 8 days) blocked the conversion of α-linolenic acid (ALA) to eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPAn-3), and reduced triacylglycerol accumulation in adipocytes. SC 26196 treatment increased the release of non-esterified fatty acids and glycerol into the culture medium and decreased the expression of the fatty acid re-esterification markers PEPCK and CD36[6].
In vivo, in athymic mice bearing U-87 MG cell xenografts, SC 26196 (30mg/kg) administered via intraperitoneal injection (every three days for four weeks). SC 26196 synergistically inhibited the growth of U-87 MG xenograft tumors when combined with radiation therapy (5Gy local X-ray irradiation, every three days)[7]. In ApcMin/+ mice bearing HT-29 colon cancer cell xenografts, dietary administration of SC 26196 (100mg/kg) for seven weeks. SC 26196 reduced number of intestinal tumors and a significant decrease in tumor size[8].
References:
[1] Sibbons CM, Irvine NA, Pérez-Mojica JE, et al. Polyunsaturated Fatty Acid Biosynthesis Involving Δ8 Desaturation and Differential DNA Methylation of FADS2 Regulates Proliferation of Human Peripheral Blood Mononuclear Cells. Front Immunol. 2018 Mar 5;9:432.
[2] Hargrave-Barnes KM, Azain MJ, Miner JL. Conjugated linoleic acid-induced fat loss dependence on Delta6-desaturase or cyclooxygenase. Obesity (Silver Spring). 2008 Oct;16(10):2245-52.
[3] Duffin KL, Obukowicz MG, Salsgiver WJ, et al. Lipid remodeling in mouse liver and plasma resulting from delta6 fatty acid desaturase inhibition. Lipids. 2001 Nov;36(11):1203-8.
[4] Obukowicz MG, Welsch DJ, Salsgiver WJ, et al. Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. J Pharmacol Exp Ther. 1998 Oct;287(1):157-66.
[5] Harmon SD, Kaduce TL, Manuel TD, et al. Effect of the delta6-desaturase inhibitor SC-26196 on PUFA metabolism in human cells. Lipids. 2003 Apr;38(4):469-76.
[6] Wang C, MacIntyre B, Mutch DM. Inhibition of Δ-6 desaturase reduces fatty acid re-esterification in 3T3-L1 adipocytes independent of changes in n3-PUFA cellular content. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jul;1867(7):159160.
[7] Wang J, Liang H, Sun M, et al. Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo. Cancer Manag Res. 2018 Dec 7;10:6779-6790.
[8] Hansen-Petrik MB, McEntee MF, Johnson BT, et al. Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis. Cancer Lett. 2002 Jan 25;175(2):157-63.
SC 26196是一种具有口服活性的Delta6去饱和酶（D6D, FADS2）抑制剂，SC 26196可抑制亚油酸和α-亚麻酸向长链不饱和脂肪酸的转化以调控脂质代谢[1-2]。SC 26196可用于炎症相关疾病、脂代谢紊乱的相关研究[3-4]。
在体外，在皮肤成纤维细胞、冠状动脉平滑肌细胞和星形胶质细胞中，SC 26196（2μM；24h）可抑制2μM [1-14C]18:2n-6的去饱和作用，并显著降低花生四烯酸、EPA和DHA的合成[5]。在3T3-L1脂肪细胞分化过程中，SC 26196（5μM；8天）可阻断α-亚麻酸（ALA）向二十碳五烯酸（EPA）和二十二碳五烯酸（DPAn-3）的转化，并减少脂肪细胞中甘油三酯的积累，SC 26196处理增加了培养基中非酯化脂肪酸和甘油的释放，降低了脂肪酸再酯化的标志物PEPCK和CD36的表达[6]。
在体内，SC 26196(30mg/kg)通过腹膜内注射（每三天一次，持续四周）处理携带有U-87 MG细胞异种移植瘤的无胸腺小鼠，SC 26196联合放射治疗（5Gy局部X射线照射，每三天一次）可协同抑制U-87 MG异种移植瘤的生长[7]。SC 26196(100mg/kg)通过饮食处理HT-2结肠癌细胞异种移植的ApcMin/+小鼠（处理七周），SC 26196导致肠道肿瘤数量减少，肿瘤尺寸显著减小[8]。
| Cell experiment [1]: | |
Cell lines | 3T3-L1 adipocytes (murine preadipocyte cell line) |
Preparation Method | 3T3-L1 pre-adipocytes were differentiated in high-glucose DMEM supplemented with 10% FBS, a standard differentiation cocktail (IBMX, DEX, insulin), and treated with the Δ-6 desaturase (D6D) inhibitor SC 26196 (5μM) throughout the 8-day differentiation process, either in the presence or absence of α-linolenic acid (ALA, 50μM) or eicosapentaenoic acid (EPA, 50μM). |
Reaction Conditions | 5μM; treatment throughout differentiation (8 days). |
Applications | SC 26196 treatment significantly reduced triacylglycerol (TAG) accumulation in differentiated 3T3-L1 adipocytes. SC 26196 inhibited the conversion of ALA to EPA and docosapentaenoic acid (DPAn-3). SC 26196 increased the release of non-esterified fatty acids (NEFA) and glycerol into the medium, elevated the NEFA/glycerol ratio, and decreased the expression of fatty acid re-esterification markers PEPCK and CD36 at both mRNA and protein levels. These effects on TAG accumulation and fatty acid re-esterification were observed independently of changes in cellular n-3 polyunsaturated fatty acid (PUFA) content. |
| Animal experiment [2]: | |
Animal models | ApcMin/+ mice (intestinal tumorigenesis model) and nude mice bearing HT-29 human colon cancer cell xenografts. |
Preparation Method | ApcMin/+ mice were fed SC 26196 mixed into their diet (AIN-93G diet or US17 diet) at a dosage of 100mg/kg/day for 7 weeks. In a separate xenograft study, nude mice were inoculated with HT-29 cells, maintained on the US17 diet, and then fed SC 26196 mixed into the same diet (100mg/kg/day) starting 5 days after tumor cell implantation. Primary tumor growth in the xenograft model was monitored. |
Dosage form | 100mg/kg/day; Administered in the diet; Daily for 7 weeks (ApcMin/+ mice) and for the study duration post-implantation (xenograft mice). |
Applications | SC 26196 treatment resulted fewer intestinal tumors in ApcMin/+ mice and reduced average primary tumor size. In nude mice bearing HT-29 xenografts, SC 26196 treatment inhibited tumor growth at 4 weeks. The anti-tumorigenic effects on ApcMin/+ mice were nullified by concomitant dietary supplementation of arachidonic acid (AA), which bypassed the SC 26196-mediated inhibition of Δ-6 desaturase. |
References: | |
| Cas No. | 218136-59-5 | SDF | |
| 别名 | ALPHA,ALPHA-二苯基-4-[(3-吡啶亚甲基)氨基]-1-吡嗪戊腈 | ||
| 化学名 | (E)-2,2-diphenyl-5-(4-((pyridin-3-ylmethylene)amino)piperazin-1-yl)pentanenitrile | ||
| Canonical SMILES | N#CC(C1=CC=CC=C1)(C2=CC=CC=C2)CCCN(CC3)CCN3/N=C/C4=CC=CN=C4 | ||
| 分子式 | C27H29N5 | 分子量 | 423.55 |
| 溶解度 | DMF: 12 mg/mL,DMF:PBS (pH 7.2) (1:4): 0.2 mg/mL,DMSO: 5 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.361 mL | 11.805 mL | 23.61 mL |
| 5 mM | 472.2 μL | 2.361 mL | 4.722 mL |
| 10 mM | 236.1 μL | 1.1805 mL | 2.361 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet